after 3 days rash developed on face ears and neck; primary immunisation: dose 1: astrazeneca, dose 2: pfizer covid vaccine; primary immunisation: dose 1: astrazeneca, dose 2: pfizer covid vaccine; high temperature; pain on the injection site; face red; feeling hot; sweating; face itchy; eyes swollen; eyes red; eyes itchy; face swollen; this is a spontaneous report received from a contactable reporter (consumer) from the regulatory authority. the reporter is the patient. regulatory number: gb-mhra-webcovid-202202141412484000-l5qpe (agency). other case identifier: gb-mhra-adr 26601665 (agency). a 48 year-old female patient received bnt162b2 (comirnaty), administration date 05feb2022 (batch/lot number: unknown) at the age of 48 years as dose 2, single for covid-19 immunisation. relevant medical history included: "period pains" (unspecified if ongoing), notes: anxiety and depression, severe periods pains on treatment for both conditions; "immunodeficiency" (unspecified if ongoing), notes: has an illness or condition, which reduces the immune response (e.g. immunodeficiency); "anxiety" (unspecified if ongoing), notes: anxiety and depression, severe periods pains on treatment for both conditions; "depression" (unspecified if ongoing), notes: anxiety and depression, severe periods pains on treatment for both conditions. the patient's concomitant medications were not reported. vaccination history included: covid-19 vaccine astrazeneca (dose 1), administration date: 14jun2021, for covid-19 immunisation. the following information was reported: off label use (medically significant), interchange of vaccine products (medically significant) all with onset 05feb2022, outcome "unknown" and all described as "primary immunisation: dose 1: astrazeneca, dose 2: pfizer covid vaccine"; feeling hot (medically significant) with onset feb2022, outcome "not recovered", described as "feeling hot"; hyperhidrosis (medically significant) with onset feb2022, outcome "not recovered", described as "sweating"; pyrexia (medically significant) with onset 05feb2022, outcome "not recovered", described as "high temperature"; vaccination site pain (medically significant) with onset feb2022, outcome "unknown", described as "pain on the injection site"; erythema (medically significant) with onset feb2022, outcome "unknown", described as "face red"; rash (medically significant) with onset 08feb2022, outcome "unknown", described as "after 3 days rash developed on face ears and neck"; pruritus (medically significant) with onset feb2022, outcome "unknown", described as "face itchy"; eye swelling (medically significant) with onset feb2022, outcome "unknown", described as "eyes swollen"; ocular hyperaemia (medically significant) with onset feb2022, outcome "unknown", described as "eyes red"; eye pruritus (medically significant) with onset feb2022, outcome "unknown", described as "eyes itchy"; swelling face (medically significant) with onset feb2022, outcome "unknown", described as "face swollen". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative covid-19 test. patient had not tested positive for covid-19 since having the vaccine. clinical course: patient reported feeling hot, pain on the injection site ,sweating, face red then after 3 days rash developed on face, ears and neck, face and eyes swollen and red and itchy. patient had not had symptoms associated with covid-19. patient was not currently breastfeeding. patient was not enrolled in clinical trial. the report was unrelated to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected